These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 30972872)

  • 41. Psoriasis: Recent progress in molecular-targeted therapies.
    Honma M; Hayashi K
    J Dermatol; 2021 Jun; 48(6):761-777. PubMed ID: 33404109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle.
    Farkas A; Kemény L
    Int Immunopharmacol; 2012 Jun; 13(2):215-8. PubMed ID: 22522054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Canavan TN; Elmets CA; Cantrell WL; Evans JM; Elewski BE
    Am J Clin Dermatol; 2016 Feb; 17(1):33-47. PubMed ID: 26649440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of IL-17F via the induction of IL-6 in psoriasis.
    Fujishima S; Watanabe H; Kawaguchi M; Suzuki T; Matsukura S; Homma T; Howell BG; Hizawa N; Mitsuya T; Huang SK; Iijima M
    Arch Dermatol Res; 2010 Sep; 302(7):499-505. PubMed ID: 20148256
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The interleukin-17 pathway in psoriasis and psoriatic arthritis: disease pathogenesis and possibilities of treatment.
    Frleta M; Siebert S; McInnes IB
    Curr Rheumatol Rep; 2014 Apr; 16(4):414. PubMed ID: 24570394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S; Thomas BJ; Ciurtin C
    Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of adalimumab therapy in adult subjects with moderate-to-severe psoriasis on Th17 pathway.
    Balato A; Schiattarella M; Di Caprio R; Lembo S; Mattii M; Balato N; Ayala F
    J Eur Acad Dermatol Venereol; 2014 Aug; 28(8):1016-24. PubMed ID: 24033358
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
    Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
    J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of psoriasis: janus kinases inhibitors and biologics for the interleukin-23/Th17 axis.
    Sun C; Xia J
    Minerva Med; 2020 Jun; 111(3):254-265. PubMed ID: 32166932
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Current treatment of psoriasis with biologics.
    Kunz M
    Curr Drug Discov Technol; 2009 Dec; 6(4):231-40. PubMed ID: 20025590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Etanercept for psoriasis: two case reports.
    Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
    Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
    Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
    J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A
    BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of psoriasis and psoriatic arthritis during pregnancy and breastfeeding.
    Kurizky PS; Ferreira Cde C; Nogueira LS; Mota LM
    An Bras Dermatol; 2015; 90(3):367-75. PubMed ID: 26131868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective.
    Kane D; FitzGerald O
    Curr Rheumatol Rep; 2004 Aug; 6(4):292-8. PubMed ID: 15251081
    [TBL] [Abstract][Full Text] [Related]  

  • 56. RANTES expression in psoriatic skin, and regulation of RANTES and IL-8 production in cultured epidermal keratinocytes by active vitamin D3 (tacalcitol).
    Fukuoka M; Ogino Y; Sato H; Ohta T; Komoriya K; Nishioka K; Katayama I
    Br J Dermatol; 1998 Jan; 138(1):63-70. PubMed ID: 9536224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bimekizumab for the treatment of psoriatic disease.
    Natsis NE; Gottlieb AB
    Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis.
    Krueger G; Callis K
    Arch Dermatol; 2004 Feb; 140(2):218-25. PubMed ID: 14967799
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Psoriasis pathogenesis and the development of novel targeted immune therapies.
    Hawkes JE; Chan TC; Krueger JG
    J Allergy Clin Immunol; 2017 Sep; 140(3):645-653. PubMed ID: 28887948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.